Radiation Oncologist at Humanitas Research Hospital. 👩🏻⚕️🇮🇹 Focused on GU cancers
Milano, Lombardia
Joined April 2021
- Tweets175
- Following1.4K
- Followers1.9K
- Likes2.2K
Raffaella Lucchini retweeted
Proud to report at #ESMO2026 the results of PE-PE trial. Oligometastatic #RCC pts have a significant benefit when pembro was added to MDT irrespectively of the type of MDT used and up to 5y from previous surgery.
Thanks to the 🇮🇹 team and special thanks to @DrChoueiri!
@OncoAlert @urotoday @myESMO @KidneyCancer @Sebastiano_Buti @ciccarese_c @fmassari79 @mimma_rizzo @elena_verzoni @MatteoSantoniMD
Raffaella Lucchini retweeted
Darolutamide with ADT and locoregional
radiation therapy (RT) in high-risk prostate cancer (DASL) showed Darolutamide reduced the risk of relapse and time to CRPC. Tolerably was good. It’s imporant to identity which patients benefit, as mortality is low, and whether latest staging with PSMA-PET changes things #ESMO26 @Silke_Gillessen @ChrisSweens1
Raffaella Lucchini retweeted
So proud of our #POPART around the 🌍 superbly presented by @PanizzaDenis 👏🏼
@StAr_MCM74 @valefacc22 @CChissotti @CiroFranzese1 @Raffa_Lucchini @roberta_muni
Post-prostatectomy RT in just 5 fractions? 👀
Ferrario et al and POPART team reports 100 pts treated with prostate-bed SBRT (32.5 Gy/5 fx):
• Late ≥G2 GU toxicity: 8.5%
• Only 1 late G2 GI event
• Just 3 in-field relapses
• 30-mo biochemical control: 74%
Very encouraging local control and toxicity—but urinary QoL remains important to watch.
#ASTRO26 #ProstateCancer #SBRT @HimanshuNagarMD @rtdess @RadOncDocJ @angela_jia_ @urotoday @TylerSbrt
Raffaella Lucchini retweeted
Amici radio‑oncologi👋🏼
con i colleghi del Gruppo GU AIRO, abbiamo preparato una survey sulla recidiva biochimica post-prostatectomia, per arrivare a pillole pratiche condivise su necessità reali💊🎯
⏳Servono solo 5 minuti
surveymonkey.com/r/Recidiva-…
#PCa #bcr #RadOnc #survey
Raffaella Lucchini retweeted
The 3.5yr OS from EV302 continues to show transformative benefit (HR 0.53 (0.45-0.63)) #ASCO26 for EV/pembro. The landmark OS for the CR population (30%) is ~90%. Median time to CR is 4.5 months (responses mature over time). Response rates of platinum chemo after EVP is 21% (OS 11 months). This should be considered a 2nd line standard. Median duration of EV was 7 months - longer in responders. Optimal duration of EV trials are needed. @OncoAlert
Raffaella Lucchini retweeted
🔬 PEACE 2 phase III: Adding pelvic RT to prostate RT + 3y ADT in very high-risk localized prostate cancer did NOT improve bPFS, MFS, CSS or OS. Borderline cPFS signal (HR 0.81, p=0.09). No added AEs. @PBlanchard_MD #ESTRO2026. @VedangMurthy what now?
Raffaella Lucchini retweeted
Update on de-escalation strategies in #mHSPC: In which patients and when can we stop the treatment? Presentation by @MatikainenMika @helsinkiuni. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4einY6t @APCCC_Lugano
Raffaella Lucchini retweeted
Which patients with synchronous, metastatic hormone-sensitive #ProstateCancer benefit from prostate radiotherapy? STOPCAP meta-analysis of individual participant data. Presented by @petegodolphin @ucl. #APCCC26 written coverage by @zklaassen_md @GACancerCenter > bit.ly/4f2TZzA @APCCC_Lugano
Two fantastic days in Castelfranco for the 4th edition of the “Advanced Uro-Oncology Days”! 😍
Well done to the scientific organisers @mat_sepu @therealmarcodoc @PorrecaAngelo and thank you again for the invitation!
#kidney #prostate #urothelial #tumours
🔗Two fantastic days in beautiful Sorrento 😍, enjoying art and learning new things.
Outstanding presentation by @tompowles1 on systemic therapy💊🧬🧪in metastatic #bladdercancer and new SOC.
Thanks to ASTELLAS
Raffaella Lucchini retweeted
Here the official position of AIRO, Italian Association of Radiotherapy and Clinical Oncology in regard to IRRADIaTE, the Italian Registry of RT-Associated Urological Treatment. @EurUrolOncol . In press. euoncology.europeanurology.c… thanks to @GiuliaMarvaso84 & @CiroFranzese1
📌 Stereotactic Body Radiation Therapy⚡️for High-Risk Prostate 🌰Cancer ➡️ our systematic review
mdpi.com/3713722 #mdpiuro via @MDPIOpenAccess
Raffaella Lucchini retweeted
🚨 Prostate cancer care has changed fast. Here’s the 2025 snapshot.
The new Lancet Seminar lays out how prostate cancer management has transformed across the disease spectrum 🌍🧬
🔍 Early disease
Active surveillance is the default for low-risk tumors, avoiding overtreatment while maintaining excellent outcomes. MRI-first pathways improve detection of clinically significant cancer.
⚖️ Localized to high-risk
Surgery and modern radiotherapy offer equivalent cancer control. Hypofractionation and SBRT shorten treatment without compromising efficacy. High-risk disease needs multimodality care.
🚀 Metastatic hormone-sensitive
ADT alone is no longer enough. Doublet or triplet therapy with ARPIs ± docetaxel is now standard, with prostate RT benefiting low-volume disease.
🎯 mCRPC era
Treatment is biology-driven: PARP inhibitors for HRR alterations, Lu-177 PSMA radioligand therapy after ARPI and taxanes, cabazitaxel preferred over ARPI sequencing.
🧠 Big takeaway
Sequencing, patient selection, toxicity, and shared decision-making matter as much as drug choice.
📖 Valérie Fonteyne et al. Lancet 2025
A must-read, practice-defining review for every GU oncologist 🔖
#OncoTwitter #MedTwitter #ProstateCancer #GUOncology @TheLancet @myESMO @OncoAlert @ASCO
Raffaella Lucchini retweeted
The STONE Trial is officially active.
With over 20 Italian centers involved, the study aims to strengthen the evidence on role of SBRT for unresectable primary renal tumors, a safe and effective ablative treatment
#SBRT #radiotherapy #kidney @GiuliaMarvaso84 @GiulioFrancoli1
Raffaella Lucchini retweeted
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: Meta-Analysis
jamanetwork.com/journals/jam…
Meta-analysis of over 10,000 patients from 13 randomized trials found that the survival benefit of androgen deprivation therapy (ADT) combined with radiotherapy is highly dependent on both treatment duration and patient risk profile, with diminishing returns beyond roughly 9–12 months and increasing non–cancer-related mortality with prolonged therapy. Optimal duration varied by disease severity—shorter or no ADT for lower-risk intermediate disease, longer courses for higher-risk groups—highlighting that extended therapy is not universally beneficial.
Because longer ADT improves cancer-specific outcomes but also increases other-cause mortality, the study emphasizes tailoring duration based on individual risk, comorbidities, life expectancy, and patient preference rather than applying uniform treatment lengths. #ProstateCancer
@NicholasZaorsky
@yilun_sun
@StatMatt9
@DrHowardSandler
@drjefstathiou
@Soum_Roy_RadOnc
@DrPaulNguyen
@jeshoag
@PBarataMD
@angela_jia_
@MSteinbergMD
@AmarUKishan
@DrSpratticus
@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@weoncologists
#AIRO2025 ⚡️💊🧬
Three days to share ideas, meet colleagues and friends 🫂, and have fun🍸🎊
A special thank you to all AIRO GU group colleagues for these two fantastic years!🩵
Raffaella Lucchini retweeted
@Fefe_Ferrario Late as always…even on social media 😅 but always thrilled to share! ✨
Amazing UroOnco days at #EMUC25 in stunning Prague 🇨🇿 — brilliant sessions, great people, and lots of take-home messages 💡
Heading back energized⚡️and with an extra souvenir: a cold 🤒
Raffaella Lucchini retweeted
So proud to share mid-term results of our POPART trial on prostate bed SBRT — core of my thesis and a project I deeply believe in ✨
Alongside #SCIMITAR & #SHORTER, another step towards the 5fx revolution! 💥
Forever🙏🏼@StAr_MCM74
50days free access⬇️
authors.elsevier.com/c/1lYbQ…
A week at @DCPTprotons ☢️🇩🇰: a great experience. Thanks to the prof @m_hoyer12 and all the staff for their hospitality!
#protontherapy
